Metrizoic Acid

Summary

Metrizoic Acid (CHEMBL1736) is an approved small-molecule radioopaque medium (ATC V08AA02).

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: V08AA02
• Chemistry: 627.94 Da · C12H11I3N2O4

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1736
Name	Metrizoic Acid
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	2528
ChEBI	CHEBI:34847
ATC	V08AA02
Molecular formula	C12H11I3N2O4
Molecular weight	627.94
InChIKey	GGGDNPWHMNJRFN-UHFFFAOYSA-N

SMILES: CC(=O)NC1=C(C(=C(C(=C1I)C(=O)O)I)N(C)C(=O)C)I

IUPAC name: 3-acetamido-5-[acetyl(methyl)amino]-2,4,6-triiodobenzoic acid

Pharmacological roles (ChEBI): radioopaque medium.

Also known as: Metrizoic acid, V08AA02, Metrizoate, METRIZOIC ACID, SID50125803, Metrizoic_acid

Parent form; salt/anhydrous children: CHEMBL1200353, CHEMBL1200423, CHEMBL2068723, CHEMBL2364738

Patent coverage: 1,104 distinct patent families (3,880 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 3,874 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).